Jeffrey Chambers, MD
Cardiovascular Disease · Minneapolis, MNNPI 1437192598
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $2,949,300 of the $3,224,243 with a category attached, or 91.5%. Teleflex LLC accounts for 65.7% of it on its own, with 28 other manufacturers making up the rest. Among cardiovascular disease clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 535 payments — averaging $6026.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$2.1M
- Vascular Solutions, Inc.$842K
- Cardiovascular Systems Inc.$119K
- Boston Scientific$76K
- ZOLL Circulation Inc$21K
- Philips North America LLC$20K
- plus $29K from 23 others
Across 169 payments — averaging $2390.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$136K
- Penumbra, Inc.$126K
- Abbott$53K
- Boston Scientific$32K
- Inari Medical, Inc.$31K
- Arrow International, Inc.$10K
- plus $15K from 4 others
Across 1 payment — averaging $25,000 each. An ownership or investment interest held by the physician or an immediate family member.
- Cardio Flow, Inc.$25K
What the payments were for
- Royalty or licence$2,949,30091%
- Consulting fees$191,8206%
- Speaking & faculty fees$58,6262%
- Travel & lodging$7,7020%
- Food & beverage$16,6041%
- Education$340%
- Entertainment$1580%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 28 | $2,118,363 |
| Vascular Solutions, Inc. | 13 | $841,634 |
| Cardiovascular Systems Inc. | 83 | $119,009 |
| Boston Scientific | 152 | $75,568 |
| ZOLL Circulation Inc | 22 | $21,086 |
| Philips North America LLC | 5 | $19,516 |
| Inari Medical, Inc. | 18 | $6,514 |
| Opsens Inc. | 37 | $4,901 |
| Medtronic(2 entities) | 26 | $3,351 |
| Cordis US CORP. | 1 | $2,400 |
| Arrow International, Inc. | 7 | $2,291 |
| Edwards Lifesciences | 32 | $1,980 |
| Merit Medical Systems Inc | 3 | $1,753 |
| Abbott | 35 | $1,525 |
| Ancora Heart, Inc. | 6 | $860 |
| Heartflow, Inc. | 10 | $819 |
| Abiomed | 20 | $809 |
| Cvrx, Inc. | 9 | $453 |
| Biotronik Inc. | 4 | $337 |
| Siemens Medical Solutions USA, Inc. | 6 | $298 |
| Cardiva Medical, Inc. | 8 | $274 |
| Recor Medical Inc | 1 | $187 |
| Shockwave Medical, Inc | 1 | $122 |
| Scpharmaceuticals Inc. | 1 | $75 |
| Stryker | 3 | $54 |
| GE HealthCare | 1 | $24 |
| Terumo Medical Corporation | 1 | $16 |
| Livanova USA, Inc. | 1 | $13 |
| Chiesi USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Arrow$2,016,210
- Catheter - Specialty Access$566,409
- SUPERCROSS MICROCATHETER (ANGLED TIP)$271,825
- Arrow FlexBlock PNB Catheter$97,656
- Coronary Orbital Atherectomy System$77,183
- CLINICAL TRIAL PRODUCT$62,000
- Diamondback Coronary$28,697
- TherOx DS2 Console$20,817
- Catheter$20,817
- Downstream Cartridge$20,817
- Stellarex$19,500
- FlowTriever$5,804
- ClotTriever$5,804
- ELUVIA$4,300
- OptoWire$3,930
- Interventional Products$3,624
- GENERAL CATHETERS$2,850
- OptoMonitor$2,693
- Peripheral Orbital Atherectomy System$2,260
- WATCHMAN Access System$2,250
How this compares
$3,224,243 in reported general payments places this provider in the 95th percentile of 451 cardiovascular disease providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 111 | $123,114 |
| JardianceEmpagliflozin | 28 | $45,488 |
| EntrestoSacubitril/Valsartan | 23 | $34,366 |
| Rosuvastatin Calcium | 283 | $4,369 |
| Metoprolol Succinate | 228 | $3,712 |
| ClopidogrelClopidogrel Bisulfate | 189 | $2,467 |
| Atorvastatin Calcium | 124 | $2,266 |
| Bumetanide | 37 | $1,961 |
| Losartan Potassium | 140 | $1,843 |
| Amlodipine Besylate | 155 | $1,586 |
| Potassium Chloride | 52 | $1,495 |
| Lisinopril | 104 | $1,224 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 68 | $1,062 |
| Ezetimibe | 32 | $956 |
| Carvedilol | 72 | $915 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Minneapolis
- Markus MeyerMinneapolis$786K
- Robert SchwartzMinneapolis$502K
- Robert VantasselMinneapolis$493K
- Nedaa SkeikMinneapolis$453K
- Joao CavalcanteMinneapolis$384K
- Inderjit AnandMinneapolis$384K
- David HurrellMinneapolis$205K
- Yader Sandoval PichardoMinneapolis$157K
- Charles HerzogMinneapolis$157K
- Tamas AlexyMinneapolis$117K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.